While they were reporting their earnings, Schering-Plough and Sanofi-Aventis executives both found themselves on a hot seat. Schering CEO Fred Hassan (photo) faced questions about how he managed the controversial Enhance study--even hearing hints that he should depart, as one analyst called the trial "the worst PR disaster I think I ever recall." That's a big change for Hassan, who's been lauded for bringing Schering out of the ditch since he took over in 2003.
Meanwhile, Sanofi's R&D chief, Paul Chew, plus some FDA staffers, are expected to be grilled by the House Energy and Commerce Committee today in a hearing about the antibiotic Ketek, which was linked with liver failure last February. The committee wants to know whether the FDA knew about a Ketek study that included falsified data.
- read the Hassan article